Factors influencing antibiotic treatment cost and outcome in critically ill patients: A 'real-life' study

Perić, Aneta; Šurbatović, Maja; Vezmar-Kovačević, Sandra; Antunović, Mirjana; Veljović, Milić; Đorđević, Dragan; Anđelić, Tamara; Zeba, Snježana; Dobrić, Silva

doi:10.2298/VSP1412102P

Akcije

dodaj u Moj izbor [0]

kako citirati ovaj članak
prikaži na oba jezika
podeli ovaj članak

Direktan link

Metrika

citati u SCIndeksu: 0
citati u CrossRef-u:0
citati u Google Scholaru:[]
posete u poslednjih 30 dana:2
preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 2 od 50

povratak na rezultate

Vojnosanitetski pregled

2014, vol. 71, br. 12, str. 1102-1108

Faktori koji utiču na cenu antibiotske terapije i ishod kod kritično obolelih pacijenata - 'real-life' studija

Perić Aneta^a, Šurbatović Maja^a, Vezmar-Kovačević Sandra^b

, Antunović Mirjana^a, Veljović Milić^a, Đorđević Dragan^a, Anđelić Tamara^c, Zeba Snježana^d, Dobrić Silva^d

^aVojnomedicinska akademija, Beograd + Univerzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd
^bUniverzitet u Beogradu, Farmaceutski fakultet, Institut za farmakokinetiku
^cVojnomedicinska akademija, Institut za medicinsku biohemiju, Beograd
^dUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Beograd

e-adresa: aneta.peric@gmail.com

Ključne reči: kritična stanja; sepsa; antibiotici; cene i analize cena; biološki pokazatelji

Sažetak

Uvod/Cilj. Kritično oboleli pacijenti imaju veliki rizik od razvoja teških infekcija u jedinicama intenzivne terapije (JIT). Nivo prokalcitonina (PCT) u cirkulaciji je povišen kod bolesnika sa bakterijskom sepsom, tako da PCT može biti koristan u praćenju antibiotske terapije. Cilj ove studije bio je da se ustanove faktori koji utiču na ishod i troškove lečenja u JIT u našoj ustanovi sa posebnim naglaskom na uticaj korišćenja serumskog nivoa PCT u vođenju antimikrobne terapije. Metode. Studija je sprovedena od avgusta 2010. godine do maja 2012. godine u Jedinici intenzivne terapije Klinike za anesteziologiju i intenzivnu terapiju Vojnomedicinske akademije (VMA) u Beogradu, Srbija. Svi kritično oboleli sa sepsom i/ili traumom koji su primljeni u JIT bili su uključeni u studiju. Studijom su obuhvaćeni samo troškovi antimikrobne terapije u JIT i troškovi PCT analize. Koristili smo cenovnik VMA za 2012. godinu. PCT u serumu je meren tehnikom homogenog imunoeseja na Brams Kriptor analizatoru. Rezultati. Studijom su bila obuhvaćena 102 bolesnika. Prosečna starost bolesnika iznosila je 55 ± 19 godina, a 61,8% bolesnika bili su muškarci. Prosečna dužina boravka u JIT (lenght of stay LOS) iznosila je 12 ± 21 dana. Postojala je statistički značajna razlika (p < 0.001) između ishoda lečenja u grupi sa sepsom u odnosu na grupu sa traumom. Bolesnici mlađi od 70 godina imali su bolju šansu da prežive. Dužina boravka, upotreba karbapenema i merenje PCT uticali su na cenu terapije u JIT. Zaključak. Dobijeni rezultati pokazuju da su godine života, dijagnoza i pol bili glavni prediktori preživljavanja kritično obolelih u JIT. Cena terapije zavisila je od dužine boravka u JIT, upotrebe karbapenema i merenja PCT, ali uticaj ovih faktora na ishod lečenja nije dostigao statističku značajnost.

Abstract

Background/Aim. Critically ill patients are at very high risk of developing severe infections in intensive care units (ICUs). Procalcitonin (PCT) levels are eleveted in the circulation in patients with bacterial sepsis and PCT might be useful in guiding antibiotic treatment. The aim of this study was to estimate factors influencing patients survival and treatment cost in ICU with special emphasis on the impact of PCT serum levels use in guiding antimicrobial therapy. Methods. The study was conducted from August 2010 to May 2012 in the Intensive Therapy Unit, Clinic of Anesthesiology and Intensive Therapy, Military Medical Academy (MMA), Belgrade, Serbia. All adult critically ill patients with sepsis and/or trauma admitted in the ICU were included in the study. This study included only the cost of antimicrobial therapy in the ICU and the cost for PCT analysis. We used prices valid in the MMA for the year 2012. PCT in serum was measured by homogeneous immunoassay on a Brahms Kryptor analyzer. Results. A total of 102 patients were enrolled. The mean patients age was 55 ± 19 years and 61.8% of patients were male. The mean length of stay (LOS) in the ICU was 12 ± 21 days. There was a statistically significant difference (p < 0.001) between the sepsis and trauma group regarding outcome (higher mortality rate was in the sepsis group, particularly in the patients with peritonitis who were mostly women). The patients younger than 70 years had better chance of survival. LOS, the use of carbapenems and PCT-measurement influenced the cost of therapy in the ICU. Conclusions. The obtained results show that age, the diagnosis and gender were the main predictors of survival of critically ill patients in the ICU. The cost of ICU stay was dependent on LOS, use of carbapenems and PCT measurement although the influence of these three factors on the outcome in the patients did not reach a statistical significance.

	Reference
	Adrie, C., Alberti, C., Chaix-Couturier, C., Azoulay, E., de Lassence, A., Cohen, Y., Meshaka, P., Cheval, C., Thuong, M., Troché, G., Garrouste-Orgeas, M., Timsit, J. (2005) Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care, 20(1): 46-58
6	Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R. (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29(7): 1303-10
	Attanasio, E., Russo, P., Carunchio, G., Basoli, A., Caprino, L. (2000) Cost-Effectiveness Study of Imipenem/Cilastatin versus Meropenem in Intra-Abdominal Infections. Dig Surg, 17(2): 164-172
1	Bouadma, L., Luyt, C., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., Bernard, M., Pasquet, B., i dr. (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet, 375(9713): 463-74
1	Brun-Buisson, C., Roudot-Thoraval, F., Girou, E., Grenier-Sennelier, C., Durand-Zaleski, I. (2003) The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med, 29(9): 1464-71
	Burchardi, H., Schneider, H. (2004) Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics, 22(12): 793-813
1	Cavaillon, J., Annane, D. (2006) Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res, 12(3): 151-70
	Cheval, C., Timsit, J.F., Garrouste-Orgeas, M., Assicot, M., de Jonghe, B., Misset, B., i dr. (2000) Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med, 26(suppl):
	Delinger, P.R., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S., i dr. (2013) Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med, 41(2): 580
	Dellinger, P.R., Levy, M.M., Carlet, J.M., Bion, J., Parker, M.M., Jaeschke, R., i dr. (2008) Surviving Sepsis Campaign: international guidelines for management for severe sepsis and septic shock: 2008. Crit Care Med, 36: 296-327
	Edbrooke, D.L., Hibbert, C.L., Kingsley, J.M., Smith, S., Bright, N.M., Quinn, J.M. (1999) The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med, 27(9): 1760-7
	Edwards, S.J., Campbell, H.E., Plumb, J.M. (2006) Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ, 7(1): 72-8
	Edwards, S.J., Wordsworth, S., Clarke, M.J. (2012) Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ, 13(2): 181-92
	Fraimow, H.S. (2013) Chipping away at unnecessary antibiotic use in the ICU, one day and one study at a time. Crit Care Med, 41(10): 2447-8
	Heyland, D.K., Johnson, A.P., Reynolds, S.C., Muscedere, J. (2011) Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med, 397(7): 17
	Honh, A., Schroeder, S., Gehn, A., Bernhardt, K., Bein, B., Wegscheider, K. (2013) Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infectious Diseases, 13: 158
	Hsueh, P., Liu, C., Shi, Z., Lee, M., Chang, F., Yang, M. (2010) Cost minimisation analysis of antimicrobial treatment for intra-abdominal infections: a multicentre retrospective study from Taiwan. Int J Antimicrob Agents, 35(1): 94-6
1	Jensen, J.U., Hein, L., Lundgren, B., Bestle, M.H., Mohr, T.T., Andersen, M.H., Thornberg, K.J., Løken, J., Steensen, M., Fox, Z., Tousi, H., Søe-Jensen, P., Lauritsen, A.Ø., i dr. (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med, 39(9): 2048-58
	Kollef, M.H., Golan, Y., Micek, S.T., Shorr, A.F., Restrego, M.I. (2011) Apprasing contemporary strategies to combat multidrug resistant gram-negative bacterial infections-Proceedings and data from the Gram-Negative Resistance Summit. Clin Infec Dis, 53(suppl 2)
1	Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J.E., Dodek, P., Wood, G., Kumar, A., Simon, D., Peters, C., Ahsan, M., Chateau, D. (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest, 136(5): 1237-48
	Lee, H., Doig, C.J., Ghali, W.A., Donaldson, C., Johnson, D., Manns, B. (2004) Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med, 32(4): 981-5
1	Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S.M., Vincent, J., Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 31(4): 1250-6
	Maki, D.G. (2004) Microbiologic diagnosis of blood culture-negative sepsis by hemofiltration. Crit Care Med, 32(4): 1075-7
	Marik, P.E. (2011) Surviving sepsis: going beyond the guidelines. Ann Intensive Care, 1(1): 17
5	Martin, G.S., Mannino, D.M., Eaton, S., Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 348(16): 1546-54
	Patil, V.K., Morjaria, J.B., de Villers, F., Babu, S.K. (2012) Associations between procalcitonin and markers of bacterial sepsis. Medicina (Kaunas), 48(8): 383-7
1	Pea, F., Viale, P., Furlanut, M. (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet, 44(10): 1009-34
	Schuetz, P., Christ-Crain, M., Müller, B. (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections: hope for hype?. Swiss Med Wkly, 139(23-24): 318-26
1	Sharma, S., Kumar, A. (2008) Antimicrobial management of sepsis and septic shock. Clin Chest Med, 29(4): 677-87, ix
	Sogayar, A.M.C., Machado, F.R., Rea-Neto, A., Dornas, A., Grion, C.M.C., Lobo, S.M.A., Tura, B.R., Silva, C.L.O., Cal, R.G.R., Beer, I., Michels, V., Safi, J., Kayath, M., Silva, E. (2008) A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics, 26(5): 425-34
	Spiegel, M.R. (1992) Theory and problems of probability and statistics. New York: McGraw-Hill, : 116-7
1	Surbatovic, M., Jevdjic, J., Veljovic, M., Popovic, N., Djordjevic, D., Radakovic, S. (2013) Immune Response in Severe Infection: Could Life-Saving Drugs Be Potentially Harmful?. Scientific World Journal
1	Tang, B.M.P., Eslick, G.D., Craig, J.C., McLean, A.S. (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis, 7(3): 210-7
	Vandijck, D.M., Depaemelaere, M., Labeau, S.O., Depuydt, P.O., Annemans, L., Buyle, F.M., Oeyen, S., Colpaert, K.E., Peleman, R.P., Blot, S.I., Decruyenaere, J.M. (2008) Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents, 31(2): 161-5
1	Vincent, J., Sakr, Y., Sprung, C.L., Ranieri, M.V., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le, G.J., Payen, D. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med, 34(2): 344-53
	Wilke, M.H. (2010) Multiresistant bacteria and current therapy: The economical side of the story. Eur J Med Res, 15(12): 571-6
	Winters, B.D., Eberlein, M., Leung, J., Needham, D.M., Pronovost, P.J., Sevransky, J.E. (2012) Long-term mortality and quality of life in sepsis: A systematic review. Crit Care Med, 38(5): 127

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP1412102P
objavljen u SCIndeksu: 12.12.2014.
metod recenzije: dvostruko anoniman

Povezani članci

Vojnosanitetski pregled (2015)
Upotreba beta-laktamskih antibiotika u jedinicama intenzivne terapije - patofiziološki, farmakokinetički, farmakodinamički i farmakoekonomski pristup
Perić Aneta, i dr.

Serb J Anest Inten Therapy (2011)
Prokalcitonin kao vodič antibiotske terapije kod kritično obolelih pacijenata
Molnár Zsolt

Vojnosanitetski pregled (2003)
Sepsa - pristup dijagnostici i lečenju
Karadaglić Đorđije, i dr.

prikaži sve [14]